HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant’s relevant medical history and/or current management of HIV infectionXx_NEWLINE_xXHIV plasma HIV-1 ribonucleic acid (RNA) below detected limit obtained by Food and Drug Administration (FDA)-approved assays (limit of detection: 75) within 4 weeks prior to registrationXx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based testsXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, however HIV-positive patients must meet the following criteria:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based testXx_NEWLINE_xXHIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider;\r\n* HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n* NOTE: A “licensed” assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studiesXx_NEWLINE_xXKnown history of HIV infectionXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive with CD4 count < (350) cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= (350) cells/microliter, and no known detectable viral load, at the time of study entry; note also that HIV testing is not required for eligibility for this protocolXx_NEWLINE_xXPositive test for HIVXx_NEWLINE_xXPatients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\r\n* They must have an undetectable viral load\r\n* They must have a CD4 count of greater than 250 cells/mcL \r\n* They must not be receiving prophylactic therapy for an opportunistic infectionXx_NEWLINE_xXPatients who are known to be human immunodeficiency virus (HIV)-positive at registration are eligible at the time of registration:\r\n1. Cluster of differentiation (CD)4+ cell count greater or equal to 250 cells/mm^3\r\n2. If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; once daily combinations that use pharmacologic boosters may not be used\r\n3. No history of non-malignancy acquired immunodeficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell countsXx_NEWLINE_xXSTEP I: Human immunodeficiency virus (HIV) infection is not excluded; known HIV positive patients must meet the following criteria:\r\n* Cluster of differentiation (CD)4 cell count >= 350/mm^3\r\n* No history of acquired immune deficiency syndrome (AIDS)-related illness\r\n* Not currently prescribed zidovudine or stavudineXx_NEWLINE_xXPatients with a known history of human immunodeficiency virus (HIV) seropositivity:\r\n* Must have undetectable viral load using standard HIV assays in clinical practice\r\n* Must have cluster of differentiation (CD)4 count >= 400/mcL\r\n* Must not require prophylaxis for any opportunistic infections (i.e., fungal, Mycobacterium avium complex [mAC], or pneumocystis jiroveci pneumonia [PCP] prophylaxis)\r\n* Must not be newly diagnosed within 12 months prior to sub-study registrationXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) may be eligible providing they meet the following additional criteria:\r\n* Cluster of differentiation (CD)4 cells >= 500/uL\r\n* Serum HIV viral load of < 25,000 IU/ml\r\n* No current antiretroviral therapy\r\n** Tests must be obtained within 28 days prior to registration; patients who are HIV positive (+) and do not meet all of these criteria are not eligible for this study (HIV/hepatitis testing are not required for patients without known infection)Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV)-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3Xx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are eligible only if they meet all of the following:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL, and an undetectable HIV viral load on standard PCR-based testsXx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A cluster of differentiation (CD)4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based testsXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:\r\n* No history of acquired immune deficiency syndrome (AIDS)-related complications other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low\r\n* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia\r\n* Patient must have serum HIV viral load of < 200 copies/mm^3\r\n* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy\r\n* Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat, stavudine, or on regimens containing stavudine or zidovudine\r\n* It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir, combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabineXx_NEWLINE_xXPatients with hepatitis B virus infection must have undetectable hepatitis B virus (HBV) on suppressive therapy and no evidence of HBV-related hepatic damage; patients with hepatitis C virus infection are eligible if complete eradication therapy has been successfully completed, and there is no detectable hepatitis C virus (HVC) or related hepatic damage; patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:\r\n* Patient must have no history of acquired immune deficiency syndrome (AIDS)-related complications, other than a history of low CD4+ T-cell count (< 200/mm3) prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low\r\n* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia\r\n* Patient must have serum HIV viral load of < 200 copies/mm^3\r\n* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy; (recommend a regimen of the integrase inhibitor dolutegravir combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine)\r\n* Protease inhibitors and once daily formulations containing cobicistat are NOT allowed\r\n* Stavudine and zidovudine (AZT) are NOT allowedXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to step 1 registration; note also that HIV testing is not required for eligibility for this protocolXx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART); and\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections; and\r\n* A CD4 count above 250 cells/uL and an undetectable HIV viral load on standard PCR-based testsXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive patients are not excluded, but to enroll, must meet all of the below criteria:\r\n* HIV is sensitive to antiretroviral therapy\r\n* Must be willing to take effective antiretroviral therapy that has minimal overlapping toxicity and pharmacokinetic interactions with protocol therapy\r\n* No history of HIV-related opportunistic disease or acquired immune deficiency syndrome (AIDS)-defining conditions within past 12 months other than historic CD4+ T-cell counts below 200 cells/mm^3\r\n* Expected long-term survival if lymphoma were not presentXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following:\r\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness\r\n* Cluster of differentiation (CD)4+ cells nadirs > 350/mm^3 within 28 days prior to registration\r\n* Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3 within 28 days prior to registration\r\n* Note: HIV+ patients who enroll on this study and are assigned to treatment with ixazomib may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4Xx_NEWLINE_xXPatients known to be human immunodeficiency virus (HIV) positive and currently receiving retroviral therapy are not eligible; note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for the studyXx_NEWLINE_xXHuman immunodeficiency virus (HIV) infected patients are eligible provided they meet all other eligibility criteria, and:\r\n* There is no prior history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ T-cell count or B-cell lymphoma\r\n* In the opinion of an expert in HIV disease, prospects for long-term survival are excellent were it not for the diagnosis of lymphoma\r\n* Use of HIV protease inhibitors as part of the anti-HIV regimen OR as a pharmacologic booster is not allowed\r\n* Zidovudine is not allowed\r\n* Once daily combination pills for HIV containing a pharmacologic booster such as cobicistat are not allowed\r\n* Patients with multi-drug resistant HIV are not eligibleXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol; this exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive.Xx_NEWLINE_xXPatients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate CD4 counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients must be on a stable anti-viral therapyXx_NEWLINE_xXPatients that are known to be positive for human immunodeficiency virus (HIV) are not eligible; note: inclusion of HIV positive patients will be considered at a later dateXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) positive must have a cluster of differentiation (CD)4 cell count be >= 350 cells/mm^3 within 14 days prior to study entry (note, however, that HIV testing is not required for entry into this protocol)Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocolXx_NEWLINE_xXHIV positive with CD4 count < 200 cells/microliter within 30 days prior to registrationXx_NEWLINE_xXHIV patients under treatment with highly active antiretroviral therapy (HAART) within 30 days prior to registration regardless of CD4 count; (Note: HIV testing is not required for eligibility for this protocol as it is self-reported; this exclusion criterion is necessary because the treatments involved in this protocol may be immunosuppressive and/or interact with HAART)Xx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based testsXx_NEWLINE_xXSevere, active co-morbidity defined as follows: \r\n* Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; Note also that HIV testing is not required for eligibility for this protocol\r\n* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol; (patients on Coumadin or other blood thinning agents are eligible for this study)Xx_NEWLINE_xXThe patient must NOT have a known positive test for human immunodeficiency virus (HIV); patients do not need to be screened for HIV; patients with HIV are excludedXx_NEWLINE_xXPatients known to be positive for HIV (the human immunodeficiency virus) may be eligible, providing they meet the following additional criteria within 28 days prior to registration:\r\n* No history of acquired immune deficiency syndrome (AIDS)-defining conditions\r\n* CD4 cells > 350 cells/mm^3\r\n* If on antiretroviral agents, must not include zidovudine or stavudine\r\n* Viral load =< 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or =< 25,000 copies HIV mRNA/mm^3 if not on cART\r\n* Highly active antiretroviral therapy (HAART) regimens are acceptable providing they have only weak P450A4 interactionsXx_NEWLINE_xXNo history of the following:\r\n* Autoimmunity requiring systemic immunosuppression within 2 years\r\n* Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following:\r\n** CD4 counts >= 350 mm^3\r\n** Serum HIV viral load of < 25,000 IU/mlXx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based testXx_NEWLINE_xXHIV positive patients.Xx_NEWLINE_xXHIV infection.Xx_NEWLINE_xXSubject is known to be HIV positive.Xx_NEWLINE_xXPatients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n* CD4+ cells >= 350/mm^3 (nadir)\r\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART\r\nPatients who are HIV+ and do not meet all of these criteria are not eligible for this studyXx_NEWLINE_xXHIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or confirmed by HIV-1 antigen or plasma HIV-1 ribonucleic acid (RNA) viral load > 1,000 copies/mL\r\n* NOTE: the term \licensed\ refers to a United States (U.S.) Food and Drug Administration (FDA)-approved kit or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally\r\n* WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral loadXx_NEWLINE_xXHuman immunodeficiency virus (HIV) test has been obtained within 42 days; participants who test positive for HIV cannot be enrolled on therapeutic part of study, but are still eligible for biology studiesXx_NEWLINE_xXParticipants known to be HIV positive (for therapeutic part of protocol, HIV participants are eligible for biology studies)Xx_NEWLINE_xXELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patient cannot have poorly controlled human immunodeficiency virus (HIV), or CD4 < 400; HIV positive patients are allowed on this study if they have a CD4 count >= 400, and are on a stable antiviral regimenXx_NEWLINE_xXELIGIBILITY CRITERIA - PHASE II (ARM D): Patient cannot have poorly controlled HIV, or CD4 < 400; HIV positive patients are allowed on this study if they have a CD4 count >= 400, and are on a stable antiviral regimenXx_NEWLINE_xXNegative HIV test at screeningXx_NEWLINE_xXKnown history of HIV or AIDSXx_NEWLINE_xXHas a known history of HIV (HIV 1/2 antibodies), active / chronic Hepatitis B or C.Xx_NEWLINE_xXHIV positiveXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy\r\n* NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXPositive serology for HIV.Xx_NEWLINE_xXPatients who have previously tested positive for human immunodeficiency virus (HIV) are NOT excluded from this study (please note: testing of all patients wishing to enroll is NOT required), but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based testsXx_NEWLINE_xXCOHORT 2: Has a known history of HIV (HIV 1/2 antibodies)Xx_NEWLINE_xXHIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infectionXx_NEWLINE_xXAny history of HIV-1 associated encephalopathyXx_NEWLINE_xXSeropositivity for HIV.Xx_NEWLINE_xXImmunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving antiviral therapy (testing is not part of the protocol)Xx_NEWLINE_xXKnown HIV positivityXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection may be eligible provided they meet the following:\r\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness\r\n* Cluster of differentiation (CD)4+ cells nadirs > 350/mm^3\r\n* Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3; please note: HIV+ patients who enroll on this study may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P450 3A4; adverse events in HIV+ patients will be reported separatelyXx_NEWLINE_xXPatients who are human immunodeficiency virus (HIV) positive on highly active anti-retroviral therapy (HAART) will be excluded from the studyXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; Note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXPositive test for the human immunodeficiency virus (HIV) unless undetectable viral load within 3 months of enrollment (HIV ribonucleic acid [RNA] less than 48 copies/mL) and on highly active antiretroviral therapy (HAART) therapyXx_NEWLINE_xXKnown seropositive for or positive viral load for human immunodeficiency virus (HIV) or positive viral loads for infectious hepatitis, type B (HBV) or C (HCV)Xx_NEWLINE_xXHIV infectionXx_NEWLINE_xXPatients known to be human immunodeficiency (HIV)-positive receiving anti-retroviral therapy are excluded from the studyXx_NEWLINE_xXPROCUREMENT: Patients with active human immunodeficiency virus (HIV) positive at time of procurement (can be pending at the time of blood draw)Xx_NEWLINE_xXA known history of HIV seropositivity or known immunodeficiencyXx_NEWLINE_xXKnown to be HIV-positiveXx_NEWLINE_xXKnown history of HIV.Xx_NEWLINE_xXDONOR: HIV-positive donorsXx_NEWLINE_xXPatients who are known to be human immunodeficiency virus (HIV)-positive at registration are eligible at the time of registration as long as:\r\n* CD4+ cell count >= 250 cells/mm^3\r\n* If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the study drugs; once daily combinations that use pharmacologic boosters may not be used\r\n* No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell countsXx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based testsXx_NEWLINE_xXA known history of HIVXx_NEWLINE_xXPatients known to be HIV positive.Xx_NEWLINE_xXKnown active HCV, HBV, and/or HIV infection.Xx_NEWLINE_xXKnown HIV seropositivityXx_NEWLINE_xXImmunocompromised patients with increased risk of opportunistic infections, including known HIV-positive patientsXx_NEWLINE_xXPROCUREMENT EXCLUSION CRITERIA: Patients with active human immunodeficiency virus (HIV) infection at time of procurementXx_NEWLINE_xXHIV positiveXx_NEWLINE_xXEXCLUSION - TREATMENT: Active infection with HIV or HTLVXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients are eligible provided the following criteria are met: CD4 count > 350/mm^3, an undetectable viral load, and not receiving prophylaxis antibioticsXx_NEWLINE_xXPatients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a cluster of differentiation (CD)4 count >= 200 cells/microliter within 180 days prior to registration as documented in the medical record; HIV testing is not required for eligibility for this protocolXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 (e.g. regimens containing ritonavir, cobicistat, efavirenz or etravirine) are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible; patients with poorly controlled HIV are not eligibleXx_NEWLINE_xXImmunocompromised patients (other than that related to the primary oncologic diagnosis or to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive are not eligibleXx_NEWLINE_xXHIV or hepatitis C - presence of viral loadXx_NEWLINE_xXSerologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and western blot, or other approved diagnostic testsXx_NEWLINE_xXEvidence of HIV infection or known HIV positive serology.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV)+ patients are eligible for the trial provided they meet the other study criteria in addition to the following:\r\n* CD4+ T-cells >= 250/mm^3\r\n* HIV sensitive to antiretroviral therapy\r\n* Zidovudine not allowed\r\n* Long term survival anticipated on the basis of HIV alone were it not for the lymphoma\r\n* No concurrent acquired immunodeficiency syndrome (AIDS)-defining illness other than the lymphomaXx_NEWLINE_xXImmunocompromised status because of current known active infection with HIV or because of the use of immunosuppressive therapies for other conditionsXx_NEWLINE_xXSubject has active infection with HIV, HBV, HCV or HTLVXx_NEWLINE_xXHas known HIVXx_NEWLINE_xXOn continuous antiretrovirals with cluster of differentiation 4 (CD4) count > 200 cells/ml with sustained undetectable viral load for at least 3 months; (HIV positive women)Xx_NEWLINE_xXPatients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\r\n* They must have a CD4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infectionXx_NEWLINE_xXKnown human immunodeficiency virus (HIV)-positive participants are ineligible; appropriate studies will be undertaken in HIV-positive participants when indicated.Xx_NEWLINE_xXHave a known history of HIV seropositivityXx_NEWLINE_xXSubjects with known HIV, active hepatitis B, or active hepatitis C (detectable RNA); HIV positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with durvalumab and/or tremelimumab; in addition, these subjects are at increased risk of lethal infections when treated with immunosuppressive therapyXx_NEWLINE_xXHave known immune system disorders (including acquired immunodeficiency syndrome [AIDS], HIV infection or hepatitis B or C); eligible patients must have a negative HIV test result within 4 weeks prior to study initiationXx_NEWLINE_xXImmune deficiency disease or known history of HIV, HBV, HCVXx_NEWLINE_xXThe patient is known to be positive for the human immunodeficiency virus (HIV). The effect of BPM31510 on HIV medications is unknown. Note: HIV testing is not required for eligibility, but if performed previously and was positive, the patient is ineligible for the study.Xx_NEWLINE_xXKnow HIV virus infectionXx_NEWLINE_xXKnown positiv test for HIVXx_NEWLINE_xXDONOR: Infection with HIVXx_NEWLINE_xXPositive HIV serology or viral RNAXx_NEWLINE_xXKnown HIV infection.Xx_NEWLINE_xXPROCUREMENT EXCLUSION CRITERIA: Patients with active human immunodeficiency virus (HIV) infection at time of procurement (can be pending at the time of blood draw)Xx_NEWLINE_xXHIV positiveXx_NEWLINE_xXEXCLUSION - TREATMENT: Known primary immune deficiency or HIV positivityXx_NEWLINE_xXKnown positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B or C; HIV patients are at increased risk of lethal infections when treated with marrow-suppressive therapyXx_NEWLINE_xXKnown HIV infection.Xx_NEWLINE_xXPART II: Negative serology for anti-HIV-1/2 and anti-HTLV 1/2Xx_NEWLINE_xXPositive serology for HIV or hepatitis CXx_NEWLINE_xXPatients with documented immunodeficiency such as HIV infection.Xx_NEWLINE_xXDONOR: HIV-positiveXx_NEWLINE_xXPositive HIV serology (previous records acceptable)Xx_NEWLINE_xXMultidrug resistant HIV not amenable to long-term suppression based on either or both:\r\n* Clinical history of poor adherence to multiple antiretroviral drugs deemed sufficient to render effective HIV control unattainable\r\n* HIV mutational analysis (genotyping and/or phenotyping) that reveals high-level resistance such that a combination regimen comprised of agents from at least two drug classes cannot be devised to suppress HIV long-term\r\n* Refusal to adhere to HAARTXx_NEWLINE_xXTREATMENT WITH SJCAR19: History of HIV infectionXx_NEWLINE_xXSeronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)Xx_NEWLINE_xXPatients who are known to be serologically positive for human immunodeficiency virus (HIV). This includes HIV patients on antiretroviral therapy due to the potential for pharmacokinetic interactions with olaparibXx_NEWLINE_xXPatients with known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required. High-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugsXx_NEWLINE_xXPatients known to be human immunodeficiency (HIV)-positive must not have multi-drug resistant HIV infection, CD4 counts < 150/ul or other concurrent acquired immunodeficiency syndrome (AIDS)-defining conditions; serologic screening for HIV is required within the 6 months prior to study enrollmentXx_NEWLINE_xXPatients serologically positive for human immunodeficiency virus (HIV), hepatitis (Hep) B, Hep C are eligible as long as the viral loads are undetectable by quantitative polymerase chain reaction (PCR); HIV positive patients must have CD4 count >= 300 cells per cubic millimeter at enrollment, be on stable antiretroviral therapy and have no reported opportunistic infections within 12 months prior to enrollmentXx_NEWLINE_xXSeronegative for human immunodeficiency virus (HIV) antibody; (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities)Xx_NEWLINE_xXSeverely compromised immunological state, including being positive for the human immunodeficiency virus (HIV)Xx_NEWLINE_xXPatients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate CD4 counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients may be on or off anti-viral therapy so long as they meet the CD4 count criteriaXx_NEWLINE_xXKnown history of HIVXx_NEWLINE_xXHuman Immunodeficiency virus (HIV) positive patients are included if CD4+ T-cell count > 200 cells/uL; on stable antiretroviral therapy for > 1 year with HIV viral load < 200 copies/mL, and no history of opportunistic infections in > 1 yearXx_NEWLINE_xXSubjects with significant history of systemic immunosuppression due to drugs or infection with HIV or HTLV 1.Xx_NEWLINE_xXHIV infectionXx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based testsXx_NEWLINE_xXHuman immunodeficiency virus (HIV) infected patients are eligible provided they meet all the other eligibility criteria of the study in addition to the following: \r\n* No history of acquired immune deficiency syndrome (AIDS)-defining conditions other than lymphoma or history of CD4+ T-cells below 200/mm^3 prior to beginning combination antiretroviral therapy (cART)\r\n* After HIV diagnosis and during treatment with cART, patients should have maintained CD4+ T-cells >= 350/mm^3 prior to lymphoma diagnosis; patients who never immune reconstituted to a stable level above 350/mm^3 are not eligible\r\n* At time of study entry CD4+ T-cells must have recovered from prior lymphoma therapy to >= 250/mm^3\r\n* At the time of study entry the HIV viral load must be undetectable by standard laboratory assay \r\n* During prior lymphoma therapy, patients must not have experienced documented infections attributed to the HIV+ status\r\n* No history of non-adherence to cART and willing to adhere to cART while on study\r\n* Antiretroviral drugs with overlapping or similar toxicity profiles as study agents not allowed:\r\n** Efavirenz not allowed\r\n** Stavudine not allowed\r\n** Zidovudine not allowed\r\n* Patients must be willing to be followed at a minimum of approximately every 3 months by physician expert in HIV disease managementXx_NEWLINE_xXKnown HIV or AIDS-related illnessXx_NEWLINE_xXParticipant has known HIV infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax) HIV testing will be performed at Screening, only if required per local guidelines or institutional standards.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) infected patients (if HIV positive)\r\n* HIV infected individuals are eligible provided they meet all the protocol eligibility criteria in addition to the following:\r\n** No history of acquired immune deficiency syndrome (AIDS) defining illness other than a historic CD4+ T-cell nadir < 200/mm^3\r\n** Prior to leukemia diagnosis, the HIV disease was uncomplicated as evidenced by:\r\n*** The CD4+ T-cell counts were generally in excess of 300/mm^3\r\n*** The HIV viral loads were less than 200 copies/ml if on anti-HIV therapy\r\n*** If the HIV is newly diagnosed or there is no history of using anti-HIV therapy, there are no AIDS defining conditions or other HIV-related symptoms\r\n*** Zidovudine is not allowed as part of the anti-HIV therapyXx_NEWLINE_xXHIV-positive; documentation of HIV-1 infection by means of any one of the following: \r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider\r\n* Documentation of receipt of antiretroviral therapy (ART) (at least two different medications) by a licensed health care provider (documentation may be a record of an ART prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name)\r\n* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay\r\nNOTE: A “licensed” assay refers to a United States (U.S.) Federal Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studiesXx_NEWLINE_xXHas active human immunodeficiency virus (HIV) infection (as manifested by presence of HIV 1/2 antibodies and/or positive HIV enzyme-linked immunosorbent assay [ELISA]/western blot assays)Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) infection as detected through any laboratory method (e.g., enzyme-linked immunosorbent assay, Western Blot, RNA PCR). [Note: Testing to confirm the absence of HIV infection is required at screening unless testing was performed by the local laboratory within 6 months prior to screening.]Xx_NEWLINE_xXPatients who are HIV positive (by self-report) or have clinical or laboratory features indicative of AIDS.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive with detectable viral load, or anyone not on stable anti?viral (highly active antiretroviral therapy [HAART]) regimenXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXParticipants with known human immunodeficiency virus (HIV); due to lack of available safety data for eribulin therapy in HIV infected patients.Xx_NEWLINE_xXHEALTHY SUBJECT: Be free of chronic illness, without known heart, lung, kidney, bleeding disorders, infectious disease (HIV, HBV or HCV infection)Xx_NEWLINE_xXHuman immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong inhibitors and strong or moderate inducers of CYP3A4\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based testXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients are excluded because these patients are at increased risk of lethal infections when treated with marrow-suppressive therapyXx_NEWLINE_xXImmunocompromised patients, e.g. patients known to be serologically positive for HIV. Patients do NOT need to be tested for HIV in order to enroll on studyXx_NEWLINE_xXSubject has active infection with HIV, HBV, HCV or HTLVXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients are eligible provided they meet all the other protocol eligibility criteria including the following:\r\n* Undetectable HIV viral load by standard clinical assay\r\n* Willing to adhere to antiretroviral therapy that has minimal overlapping toxicity or pharmacokinetic interactions with protocol therapy\r\n* CD4+ T cell counts of 200/mm^3 or greater\r\n* No acquired immunodeficiency syndrome (AIDS)-defining events other within the past 12 months\r\n* Near normal life expectancy if not for the presence of the cancer\r\nAlso, HIV-positive patients must not be on HIV medications considered to be inhibitors or inducers of CYP3A4Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive patients who are otherwise eligible for this study may be enrolled if they meet the following requirements:\r\n* Are seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period\r\n** Are on maximally active anti-HIV regimen to control disease as determined appropriate by the ID/HIV physicians; for the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor\r\n* CD4+ >= 50/uL\r\n* HIV ribonucleic acid (RNA) viral load =< 100,000 copies per mL on each of samples 4 weeks apart; the most recent level must be within 30 days of enrollmentXx_NEWLINE_xXKnown HIV, HBV, or HCV infection;Xx_NEWLINE_xXKnown human immunodeficiency virus (HIV)-positive unless on highly active antiretroviral therapy (HAART), and/or known Hepatitis B or C on treatment. Drug interactions between those agents and these experimental agents are wholly unknown (screening not required).Xx_NEWLINE_xXKnown HIV-positive subjects on combination anti-retroviral therapy due to the potential for PK interactions with the study agent.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients may be considered for this study only after consultation with a National Institute of Allergy and Infectious Diseases (NIAID) physicianXx_NEWLINE_xXKnown history of HIV infection (testing not mandatory).Xx_NEWLINE_xXHIV-positive tetralogy of fallot (TET) patients are ineligibleXx_NEWLINE_xXParticipant has known Human Immunodeficiency Virus (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax). HIV testing will be performed at Screening, if required per local guidelines or institutional standards.Xx_NEWLINE_xXPatients who are HIV positive (by self-report) or have clinical or laboratory features indicative of AIDS.Xx_NEWLINE_xXIf HIV positive, receipt of anti-retroviral therapy continuously for at least 6 months prior to enrollmentXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) are eligible for the study provided they meet the other protocol criteria in addition to the following: \r\n* Undetectable HIV load by standard polymerase chain reaction (PCR) clinical assay\r\n* Absolute CD4 count of >= 200 mm^3\r\n* Willing to maintain adherence to combination antiretroviral therapy\r\n* No history of acquired immunodeficiency syndrome (AIDS) defining condition (other than lymphoma or CD4 cell count < 200 mm^3)\r\n* Likely to have near normal lifespan if not for the presence of relapsed/refractory lymphoma\r\n**Patients with evidence of hepatitis B virus (HBV) are eligible provided there is minimal hepatic injury and the patient has undetectable HBV on suppressive HBV therapy; patient must be willing to maintain adherence to HBV therapy\r\n** Patients with previously treated and eradicated hepatitis C virus (HCV) who have minimal hepatic injury are eligibleXx_NEWLINE_xXKnown to be positive for the human immunodeficiency virus (HIV); note: HIV-testing is not required for eligibility, but if performed previously and was positive, the subject is ineligibleXx_NEWLINE_xXHIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of ART (at least three different medications) by a licensed health care provider (documentation may be a record of an antiretroviral therapy (ART) prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name);\r\n* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n* NOTE: a “licensed” assay refers to a United States (U.S.) Food and Drug Administration (FDA)-approved assay, which is required for all investigational food drug (IND) studiesXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) positive (+) patients; EXCEPTION: if they meet the following additional criteria =< 28 days prior to registration:\r\n* CD4 cells >= 500/mm^3\r\n* Viral load of < 50 copies HIV messenger (m) ribonucleic acid (RNA)/mm^3 if on combination antiretroviral therapy (cART) or < 10,000 copies HIV mRNA if not on cART\r\n• No zidovudine or stavudine as part of cARTXx_NEWLINE_xXKnown carriers of HIV antibodiesXx_NEWLINE_xXPatients should have no evidence, as listed below, of being immunocompromised:\r\n• Human immunodeficiency virus (HIV) positivity due to the potential for decreased tolerance and risk for severe side effects\r\n• Hepatitis B or C positivityXx_NEWLINE_xXAny HIV statusXx_NEWLINE_xXKnown history of HIV, HBV or HCV infection.Xx_NEWLINE_xXKnown HIV-infected patientsXx_NEWLINE_xXKnown human immunodeficiency virus (HIV)-positivity AND actively being treated with highly active antiretroviral therapy (HAART)Xx_NEWLINE_xXHas a known history of human immunodeficiency virus (HIV); HIV-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excludedXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy may be eligible if there are no pharmacokinetic interactions with the agents used on the study, stable on chimeric antigen receptor T cell (CART) therapy and cluster of differentiation (CD)4 is > 200 and viral load is undetectableXx_NEWLINE_xXKnown positive serology for human immunodeficiency virus (HIV), due to potential drug-drug interactions between anti-retroviral medications and the study drugsXx_NEWLINE_xXHIV positiveXx_NEWLINE_xXActive autoimmune disorders, including patients known to be human immunodeficiency virus (HIV) positive, or those requiring chronic steroid administration (excluding inhaled steroids)Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive; HIV results will be determined by nucleic acid testingXx_NEWLINE_xXPRIOR TO CELL PROCUREMENT: Active infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV), hepatitis C virus (HCV) (can be pending at the time of cell procurement; only those samples confirming lack of active infection will be used to generate transduced cells) defined as not being well controlled on therapy; patients are required to have negative HIV antibody or negative HIV viral load, negative HTLV1 and 2 antibodies, negative HCV antibody or viral loadXx_NEWLINE_xXPRIOR TO LYMPHODEPLETION: Active infection with HIV, HTLV, HCV (can be pending at the time of cell procurement; only those samples confirming lack of active infection will be used to generate transduced cells) defined as not being well controlled on therapy; patients are required to have negative HIV antibody or negative HIV viral load, negative HTLV1 and 2 antibodies, negative HCV antibody or viral loadXx_NEWLINE_xXPRIOR TO INFUSION OF ATLCAR.CD30 CELLS: Active infection with HIV, HTLV, HCV (can be pending at the time of cell procurement; only those samples confirming lack of active infection will be used to generate transduced cells) defined as not being well controlled on therapy; patients are required to have negative HIV antibody or negative HIV viral load, negative HTLV1 and 2 antibodies, negative HCV antibody or viral loadXx_NEWLINE_xXKnown HIV-positive or Hepatitis CXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXWilling to have documentation of HIV statusXx_NEWLINE_xXCD4 count >= 100 cells/uL if HIV-infectedXx_NEWLINE_xXPatients with other diseases that in the opinion of the treating physician pose a higher risk for treatment with ibrutinib therapy including active human immunodeficiency virus (HIV) infection and bleeding disordersXx_NEWLINE_xXKnown history of HIV, HBV or HCV infection.Xx_NEWLINE_xXKnown positive for HIVXx_NEWLINE_xXPatient must be willing to undergo testing for human immunodeficiency virus (HIV) if not tested within the past 6 months. If HIV+ positive, patient will be eligible if: his/ her CD4+ count ? 300/?L; his/her viral load is undetectable; he/she is currently receiving highly active antiretroviral therapy (HAART).Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) infection, unless receiving effective antiretroviral therapy with undetectable viral load and normal CD4 countsXx_NEWLINE_xXKnown to be HIV-positiveXx_NEWLINE_xXPatients who are known to have HIV infection/seropositivity.Xx_NEWLINE_xXPatients with well controlled human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and viral load is < 50 copies/mlXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial; patients with HIV on antiretroviral therapy other than zidovudine (AZT) and/or stavudine and without prior acquired immunodeficiency syndrome (AIDS) defining conditions and adequate CD4 count (> 400) are eligibleXx_NEWLINE_xXImmune deficiency disease or known history of HIV, HBV, HCVXx_NEWLINE_xXFor dose-escalation cohort only, known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required; HIV positive patients will be eligible for the dose-expansion cohortXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) infection are eligible if not on antiviral agents and cluster of differentiation (CD)4 counts are adequate (>= 500)Xx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA:\r\nHuman immunodeficiency virus (HIV)-positive patients on antiretroviral therapy are ineligible; however, patients with long-standing (> 5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/uL) may be eligible if the PI determines no anticipated clinically significant drug-drug interactionsXx_NEWLINE_xXPHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHIV-positive patients on anti-retroviral therapy are ineligible; however, patients with long-standing (> 5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/uL) may be eligible if the PI determines no anticipated clinically significant drug-drug interactionsXx_NEWLINE_xXPHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHIV-positive patients on combination antiretroviral therapy are ineligible; however, patients with long-standing (> 5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/uL) may be eligible if the PI determines no anticipated clinically significant drug-drug interactionsXx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nHIV-positive patients on anti-retroviral therapy are ineligible; however, patients with long-standing (> 5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/?L) may be eligible if the PI determines no anticipated clinically significant drug-drug interactionsXx_NEWLINE_xXDONOR: HIV positiveXx_NEWLINE_xXHuman Immunodeficiency Virus (HIV)-infection is not an exclusion criterion if it is controlled with anti-retroviral drugs that are unaffected by concomitant enzalutamide.Xx_NEWLINE_xXAT THE TIME OF INFUSION: HIV positivityXx_NEWLINE_xXHIV-positiveXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive (+) patients with cluster of differentiation 4 (CD4) counts >= 250 cells/mm^3 on anti-viral therapyXx_NEWLINE_xXPatients who have known human immunodeficiency virus (HIV) positivity must be on a 3-drug antiviral regimen that does not include zidovudine, and must have a cluster of differentiation (CD)4 count > 100/mm^3 and virus load < 5000 copies/ml, and are placed on a regimen to prevent pneumocystis pneumonia (PCP) reactivation during treatmentXx_NEWLINE_xXBecause patients with immune deficiency are not expected to respond to this therapy, human immunodeficiency virus (HIV)-positive patients are excluded from the studyXx_NEWLINE_xXKnown human immunodeficiency virus (HIV)-positive individuals; high-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs; a clinical trial designed to address these interaction issues is more appropriate than this phase 2 studyXx_NEWLINE_xXHIV-1 seropositiveXx_NEWLINE_xXKnown HIV, or active hep B or hep C infection (detected positive by PCR).Xx_NEWLINE_xXPatients with a detectable human immunodeficiency virus (HIV) viral load or who are HIV-positive AND have a resistant genotypeXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible provided that they meet the following criteria in addition to the other protocol criteria: \r\n* Cancer as the only acquired immunodeficiency syndrome (AIDS)-defining condition\r\n* Cluster of differentiation (CD)4 cell count >= 250\r\n* Treatment sensitive HIV and prospects for long term survival on the basis of HIV disease alone\r\n* Willing to take anti-HIV therapy that will have minimal potential for pharmacokinetic interactions with GDC-0449Xx_NEWLINE_xXPROCUREMENT: Patients with active human immunodeficiency virus (HIV) infection at time of procurement (can be pending at the time of blood draw)Xx_NEWLINE_xXPART 2: History of HIV infectionXx_NEWLINE_xXSubjects who are known to be HIV positiveXx_NEWLINE_xXPatients with known HIV diseaseXx_NEWLINE_xXKnown history of HIV infection.Xx_NEWLINE_xXKnown history of HIV, HBV or HCV infection.Xx_NEWLINE_xXHIV positive.Xx_NEWLINE_xXPatients currently known to be positive for, HIV, hepatitis B or C.Xx_NEWLINE_xXThe patient has a history of human immunodeficiency virus (HIV) or other known cause of immunosuppression, or is actively taking immunosuppressive medications due to organ transplantation, rheumatoid disease, or other medical conditionsXx_NEWLINE_xXKnown human immunodeficiency virus (HIV)-positive patients are excluded from the study; for patients receiving combination anti-retroviral therapy; screening for HIV status will not be performedXx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive patients are allowed on this study if they have a CD4 count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excludedXx_NEWLINE_xXRANDOMIZED PHASE II (ARMS K AND L): HIV positive patients are eligible provided they meet the other protocol criteria including the following:\r\n* Long term survival expected were it not for the cHL\r\n* HIV viral loads undetectable by standard clinical HIV testing\r\n* Willing to adhere to effective combination antiretroviral therapyXx_NEWLINE_xXMust not be HIV, HBV or HCV positiveXx_NEWLINE_xXKnown immunosuppressed conditions or active immunosuppressive therapy such as organ transplantation (including bone marrow transplant), high dose steroids, or human immunodeficiency virus (HIV); although a documented negative HIV test is not mandatory for enrollment, patients felt to have a high clinical suspicion for HIV will need to test negative prior to enrollment; use of topicals or eye drops containing steroids is acceptable; inhaled steroids are excludedXx_NEWLINE_xXPatients who are known to be HIV or hepatitis C positive.Xx_NEWLINE_xXDONOR: HIV or human T-lymphotropic virus (HTLV) seropositiveXx_NEWLINE_xXKnown HIV-positive serology.Xx_NEWLINE_xXAny HIV statusXx_NEWLINE_xXFor patients with HIV-associated KS:\r\n* Must be receiving, and adherent to, a highly active antiretroviral therapy (HAART) regimen consistent with current clinical guidelines\r\n* Must have been receiving HAART for at least one month\r\n* Must have achieved an HIV viral load (VL) < 10,000 copies/mLXx_NEWLINE_xXSerology:\r\n* Seronegative for human immunodeficiency virus (HIV) antibody (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive may have decreased immune-competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities)Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive (+) patients with CD4 counts >= 250 cells/mm^3 on anti-viral therapy are eligible for the studyXx_NEWLINE_xXPatients with known active human immunodeficiency virus (HIV) infection; patients with chronic HIV with a CD4 > 250, undetectable viral load by PCR, without opportunistic infection, and on a stable regimen of highly active anti-retroviral therapy (HAART) therapy would be eligibleXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXIf there is clinical suspicion of acquired immune deficiency syndrome (AIDS), a human immunodeficiency virus (HIV) test must be done within 42 days prior to registration; Note: HIV positive patients with a cluster of differentiation (CD)4+ T cell count > 200 per uL of blood and > 14% of all lymphocytes are eligible for this trialXx_NEWLINE_xXKnown history of human immunodeficiency virus (HIV) seropositivity as these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy and the potential pharmacokinetic interaction between antiretroviral therapy and the investigational agentXx_NEWLINE_xXNo uncontrolled bacterial, viral, or fungal infection (infection is permitted if there is evidence of response to medication)\r\n* Note: human immunodeficiency virus (HIV)-infected patients are potentially eligible; eligibility of HIV-infected patients will be determined on a case-by-case basisXx_NEWLINE_xXHIV infectionXx_NEWLINE_xXHuman immunodeficiency virus (HIV) infection, unless the patient is receiving effective antiretroviral therapy with undetectable viral load and normal CD4 countsXx_NEWLINE_xXKnown HIV positivityXx_NEWLINE_xXThose who are HIV-positive will be excluded from the studyXx_NEWLINE_xXPatients known to be human immunodeficiency virus (HIV)-positive (the concern for opportunistic infection and hematologic reserve are considered to be significantly greater in this population)Xx_NEWLINE_xXPatients with a known history of HIV.Xx_NEWLINE_xXKnown HIV positive patientsXx_NEWLINE_xXKnown to be HIV-positiveXx_NEWLINE_xXParticipants with known human immunodeficiency virus (HIV); due to lack of available safety data for eribulin therapy in HIV-infected participantsXx_NEWLINE_xXDiagnosis of HIV or evidence of active HBV or HCVXx_NEWLINE_xXHas a known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibodies); patients with treated HIV, as evidenced by stable CD4 > 200 for at least 6 months, are eligibleXx_NEWLINE_xXHIV infection or a known HIV-related malignancy.Xx_NEWLINE_xXKnown HIV, HBV, or HCV infection.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients are ineligible due to the risks associated with immune checkpoint blockadeXx_NEWLINE_xXKnown seropositive for HIVXx_NEWLINE_xXPatients with immune deficiency have impaired immune responses, therefore, known human immunodeficiency virus (HIV)-positive patients are excluded from the studyXx_NEWLINE_xXKnown HIV-positiveXx_NEWLINE_xXPatients who are HIV positiveXx_NEWLINE_xXPatients who are known to be HIV-positive.Xx_NEWLINE_xXSubject has known HIV infectionXx_NEWLINE_xXKnown to be HIV+Xx_NEWLINE_xXPositive results from HIV serology testing, if any available.Xx_NEWLINE_xXHistory of HIV infection.Xx_NEWLINE_xXPatients known to be HIV positive are ineligible.Xx_NEWLINE_xXHIV positiveXx_NEWLINE_xXKnown HIV positive or on active anti-retroviral therapyXx_NEWLINE_xXHistory of HIV positiveXx_NEWLINE_xXKnown history of HIV or AIDS.Xx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active antiretroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR) -based testsXx_NEWLINE_xXPatients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 4 weeks prior to randomization:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART) and;\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections; and\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based testsXx_NEWLINE_xXHuman immunodeficiency virus (HIV) infected patients (defined as HIV-1/HIV-2 antibody positive).Xx_NEWLINE_xXKnown HIV infection.Xx_NEWLINE_xXKnown history of HIV (HIV 1/2 antibodies).Xx_NEWLINE_xXEvidence of active HepB, HepC, or HIV infectionXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): Patients who are human immunodeficiency virus (HIV) positive are eligible if they have undetectable HIV viral load and CD4+ T-cell count >= 250/mm^3Xx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 2): Patients who are human immunodeficiency virus (HIV) positive are eligible if they have undetectable HIV viral load and CD4+ T-cell count >= 250/mm^3Xx_NEWLINE_xXKnown infection with HIV (testing of patients not known to be infected with HIV is not required prior to study entry)Xx_NEWLINE_xXPatients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXKnown history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Anti-retroviral agents are known to have potential adverse pharmacokinetic interactions with nivolumab and/or BMS-813160. IN addition, patients not on anti-retroviral agents, regardless of HIV viral load, are at increased risk of lethal infections with marrow-suppressive therapy including chemotherapy. Testing for HIV must be performed at sites mandated by local requirements.Xx_NEWLINE_xXPositive screening tests for human immunodeficiency virus (HIV), hepatitis (Hep) B, Hep C, active tuberculosis or recent (< 2 week ago) clinically significant infection or evidence of active HIV, Hep B, or Hep C. (Note: If positive results are not indicative of true active or chronic infection, the patient can be treated.)Xx_NEWLINE_xXPositive screening tests for HIV, Hep B, and Hep C. If positive results are not indicative of true active or chronic infection, the patient can be treated.Xx_NEWLINE_xXFor human immunodeficiency virus (HIV)+ patients: documented HIV-1 infection with CD4 count > 200 cells/mm^3 and viral load < 75 copies/mL, within 28 days of day 0.Xx_NEWLINE_xXOther untreated coexisting HIV related malignancies.Xx_NEWLINE_xXPositive screening tests for human immunodeficiency virus (HIV), hepatitis (Hep) B, and Hep C; if positive results are not indicative of true active or chronic infection, the patient can be treatedXx_NEWLINE_xXHIV positive with CD4 count < 200 cells/microliter; note that patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter prior to registration; note also that HIV testing is not required for eligibility for this protocolXx_NEWLINE_xXKnown human immunodeficiency virus (HIV)-1 infection status, as documented by any nationally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA], test kit, and confirmed by approved test at each study site; United States (U.S.) participants only: alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either:\r\n* Approved diagnostic tests, or\r\n* The referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection\r\n** Participants enrolled outside the U.S. must have a confirmatory diagnostic test sequence as appropriate per national standards, detailed as above, performed regardless of prior documented HIV status; for HIV-negative participants, testing must be performed no more than 1 month prior to study enrollment; NOTE: the term “licensed” refers to a U.S. Food and Drug Administration (FDA)-approved kit or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally; WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an enzyme/chemiluminescence immunoassay (E/CIA) that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 ribonucleic acid (RNA) viral loadXx_NEWLINE_xXNo human immunodeficiency virus (HIV) infection; patients with immune dysfunction are at a significantly higher risk of toxicities from intensive immunosuppressive therapiesXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive subjects positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive subjects must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) \r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based testXx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based testsXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV), hepatitis B or C infections; testing to prove negative status is not required for enrollment unless it is deemed necessary for usual medical care of the patientXx_NEWLINE_xXARM B: Known HIV infectionXx_NEWLINE_xXImmunocompromised patients, including patients known to be HIV positiveXx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are not excluded from this study, but HIV-positive patients must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong or moderate CYP3A4 inducers or inhibitors\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections \r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based testXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) infection are eligible if being treated with non-interacting antiretroviral (ARV) agents or be willing to stop ARV for the protocolXx_NEWLINE_xXPatients with a known history of human immunodeficiency virus (HIV) are eligible, if they meet all of the following conditions:\r\n* No history of HIV complications with the exception of cluster of differentiation (CD)4 count < 200 cells/mm^3\r\n* No antiretroviral therapy with overlapping toxicity such as myelosuppression\r\n* HIV viral loads below the limit of detection\r\n* No history of highly active antiretroviral therapy (HAART)-resistant HIVXx_NEWLINE_xXHealthy human immunodeficiency virus (HIV)-infected patients are eligible, provided that they meet all the other study criteria in addition to the following (HIV testing is not required for study enrollment):\r\n* CD4+ cell count >= 250/mm^3\r\n* HIV viral loads undetectable by standard clinical testsXx_NEWLINE_xXDONOR: HIV positiveXx_NEWLINE_xXHIV-1 seropositiveXx_NEWLINE_xXHIV plasma viral load < 50 copies/mlXx_NEWLINE_xXPatients who are human immunodeficiency virus (HIV) positive may participate if they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\r\n* They must have a cluster of differentiation (CD)4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infectionXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria: cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active anti-retroviral therapy (HAART) is allowedXx_NEWLINE_xXDONOR: HIV-positiveXx_NEWLINE_xXThe first six patients enrolled in the Flt3L arm of the study cannot be human immunodeficiency virus (HIV)-positive; after the evaluation of safety in the first 6 patients, HIV-positive patients with adequate immune function as evidenced by stable cluster of differentiation (CD)4 counts >= 350/mm^3 are allowed to participate if the following criteria are met:\r\n* Maintained on stable antiretroviral therapy with no significant drug interactions, and \r\n* No recent history of acquired immune deficiency syndrome (AIDS) indicator conditions (> 2 years from enrolling in trial), and \r\n* Physician providing patient’s care for HIV must also approve of patient entering the studyXx_NEWLINE_xXKnown history of immunodeficiency disorder other than HIV-positive statusXx_NEWLINE_xXSeronegative for human immunodeficiency virus (HIV) antibody; Note: the experimental treatment being evaluated in this protocol depends on an intact immune systemXx_NEWLINE_xXPatients with a known history of human immunodeficiency virus (HIV) seropositivity: must have undetectable viral load using standard HIV assays in clinical practice; must have cluster of differentiation (CD)4 count >= 400/mcL; must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis); must not be newly diagnosed within 12 months prior to re-registrationXx_NEWLINE_xXPatients with a known history of human immunodeficiency virus (HIV) seropositivity: 1. Must have undetectable viral load using standard HIV assays in clinical practice; 2. Must have cluster of differentiation (CD)4 count >= 400/mcL; 3. Must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis); 4. Must not be newly diagnosed within 12 months prior to re-registrationXx_NEWLINE_xXPatients with a known history of human immunodeficiency virus (HIV) seropositivity:\r\n* Must have undetectable viral load using standard HIV assays in clinical practice\r\n* Must have cluster of differentiation (CD)4 count >= 400/mcL\r\n* Must not require prophylaxis for any opportunistic infections (i.e., fungal, mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis)\r\n* Must not be newly diagnosed within 12 months prior to re-registrationXx_NEWLINE_xXPatients with concurrent human immunodeficiency virus (HIV) infection may be enrolled if compliant with 3 or more drug anti-retroviral regimen and virus load less than 50 copies/ml and CD4 count greater than 250 cells/ml, and no concurrent opportunistic infection or other malignancyXx_NEWLINE_xXHIV seropositive at or before the time of lymphoma diagnosis; all HIV positive patients are eligible regardless of HIV viral load or antiviral therapy (ART) status; all patients on study will receive ART as per standard guidelinesXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; note: HIV testing is not required for entry into this protocolXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) are not eligible if cluster of differentiation (CD)4 count is =< 200 cell/mm^3 or if receiving antiretroviral therapyXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) who have cluster of differentiation (CD)4+ T cell counts >= 500 cells/mm^3 and who do not require antiretroviral therapy are eligibleXx_NEWLINE_xXPatients with absolute lymphocyte count of < 500, who are known to be human immunodeficiency virus (HIV) positive, who have clinically significant active autoimmune disease, or are receiving immunosuppression following solid organ or stem cell transplantXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients on antiviral drugs and/or cluster of differentiation (CD)4 count is inadequate (< 500); if neither condition exists, HIV-positive patients are eligibleXx_NEWLINE_xXPatients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n* Cluster of differentiation (CD)4 cells >= 500/mm^3\r\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART\r\n* Patients who are HIV+ and do not meet all of these criteria are not eligible for this studyXx_NEWLINE_xXDONOR: Individuals who are HIV-positiveXx_NEWLINE_xXPatients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection who are taking chronic anti-retroviral therapy (HAART) are ineligible if there is a potential for drug-drug interactions with the chemotherapeutic agents; patients with a known confirmed diagnosis of HIV infection who meet standard eligibility criteria and are not taking HAART with a potential for drug-drug interactions are eligibleXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients will be excluded unless antiretroviral therapy can be safely withheld during chemotherapy administration, based on clinical determination of infectious disease team evaluationXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) infection are ineligible due to risk of pharmacokinetic interactions between anti-retroviral therapy and the study drugs, as well as potential for significant immunosuppression and serious infections with mTOR inhibitionXx_NEWLINE_xXHIV-positive subjects with a CD4 count < 200 cells/?L are excluded due to the increased risk of lethal infections when treated with marrow-suppressive chemotherapy(87)\r\n* NOTE: subjects with HIV infection and a CD4 count >= 200 cells/?L are eligible but combination antiretroviral therapy should be held during administration of chemotherapy due to the potential for pharmacokinetic interactions with decita-bine, cytarabine or daunorubicin. Antiretroviral therapy may be resumed 24 hours after completion of the last dose of induction chemotherapyXx_NEWLINE_xXImmunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 counts < 200Xx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection (antibody positive with positive confirmatory molecular test)Xx_NEWLINE_xXPatient must have documentation of negative human immunodeficiency virus (HIV)-1 testing within 6 weeks prior to study registration (separate counseling and consent as per institutional guidelines)Xx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection are eligible; patients with HIV infection must meet the following: no evidence of co-infection with hepatitis B or C; CD4+ count > 400/ul; no evidence of resistant strains of HIV; on anti-HIV therapy with an HIV viral load < 50 copies HIV RNA/mL; no history of acquired immunodeficiency syndrome (AIDS)-defining conditions; no zidovudine or stavudine are allowed owing to overlapping toxicity with chemotherapyXx_NEWLINE_xXDocumentation of HIV infection at any time prior to study entry; documentation may be molecular (detectable viral ribonucleic acid [RNA] by polymerase chain reaction [PCR]), serologic (positive enzyme-linked immunosorbent assay [ELISA] and positive Western blot), or other federally approved licensed HIV test; prior documentation of HIV seropositivity is acceptableXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) are excluded; appropriate studies may be undertaken in patients with HIV and those receiving combination anti-retroviral therapy in the futureXx_NEWLINE_xXKnown HIV positivityXx_NEWLINE_xXDonors: HIV positiveXx_NEWLINE_xXPatients with HIV disease are eligible for this study provided that:\r\n* Patients will be seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period\r\n* Must be on a maximally active anti-HIV regimen to control disease as determined appropriate by the ID/HIV physicians; for the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor\r\n* Cluster of differentiation (CD)4+ >= 50/uL\r\n* HIV ribonucleic acid (RNA) viral load =< 100,000 copies per mL on each of samples 4 weeks apart; the most recent level must be within one month of enrollmentXx_NEWLINE_xXHIV infectionXx_NEWLINE_xXPatients known to be human immunodeficiency virus (HIV) positive and receiving highly active anti-retroviral therapy (HAART)Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) infection is not excluded; HIV+ patients must meet the following criteria:\r\n* Cluster of differentiation (CD)4 cell count >= 350/mm^3\r\n* No history of acquired immune deficiency syndrome (AIDS)-related illness\r\n* Not currently prescribed zidovudine or stavudineXx_NEWLINE_xXKnown HIV or AIDS-related illnessXx_NEWLINE_xXCurrent clinically active infectious disease (including positive HIV serology or viral RNA)Xx_NEWLINE_xXPatients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate cluster of differentiation 4 (CD4) counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml; patients may be on or off anti-viral therapy so long as they meet the CD4 count criteriaXx_NEWLINE_xXHIV positive test within 8 weeks of screeningXx_NEWLINE_xXKnown history of infection with HIV.Xx_NEWLINE_xXKnown history of infection with HIV.Xx_NEWLINE_xXHIV positive patientsXx_NEWLINE_xXKnown HIV (HIV testing will be performed at screening if required by local regulations) in participants to be pretreated with obinutuzumabXx_NEWLINE_xXPositive human immunodeficiency (HIV) test at screening or at any time prior to screeningXx_NEWLINE_xXPatients must not have any known immune deficiencies; patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; therefore, known human immunodeficiency virus (HIV) positive patients receiving combination anti-retroviral therapy are excluded from the studyXx_NEWLINE_xXKnown infectious disease including HIV positivity or AIDS-related illness, HBV and HCVXx_NEWLINE_xXKnown HIV or AIDSXx_NEWLINE_xXPatients with active human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral treatment (HAART) is allowedXx_NEWLINE_xXImmunocompromised patients, including patients with known HIV infection;Xx_NEWLINE_xXKnown history of testing positive for HIV or AIDSXx_NEWLINE_xXPatients with HBV, HCV or HIV infectionXx_NEWLINE_xXHIV negativeXx_NEWLINE_xXHIV positive patients with advanced immune suppression and evidence of HIV resistant to all combinations of antiretroviral therapy considered at high risk of non-lymphoma related death within 12-months due to other acquired immune deficiency syndrome (AIDS) complications should not be enrolled on the studyXx_NEWLINE_xXPatients who are known to be human immunodeficiency virus positive (HIV+) may be eligible providing they meet all of the following additional criteria:\r\n* Patients must have no history of acquired immunodeficiency syndrome (AIDS) defining events\r\n* Cluster of differentiation (CD)4 cells >= 500/mm^3\r\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cARTXx_NEWLINE_xXHas a congenital or acquired immunodeficiency, including subjects with known history of infection with human immunodeficiency virus (HIV) NOTE: HIV-positive subjects who are taking antiretroviral therapy are ineligible due to potential PK interactions with tazemetostat.Xx_NEWLINE_xXHas a known history of HIV (HIV 1/2 antibodies).Xx_NEWLINE_xXKnown history of HIV positive statusXx_NEWLINE_xXActive infection with HIV, HBV, HCV or HTLV as minimally defined below:Xx_NEWLINE_xXPositive serology for HIV.Xx_NEWLINE_xXNo known HIV-positive or AIDS unless patient is on a stable highly active antiretroviral therapy (HAART) regimen, have CD4 (cluster of differentiation 4) counts >350, with no detectable viral load on quantitative polymerase chain reaction testXx_NEWLINE_xXPatients testing positive to one of the following viruses: HIV, HBV and HCV within the last 6 months;Xx_NEWLINE_xXSubjects with known HIV infectionXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following:\r\n* No evidence of co-infection with hepatitis B or C\r\n* CD4+ cell count >= 400/mm^3\r\n* No evidence of resistant strains of HIVXx_NEWLINE_xXPatients who are known to be human immunodeficiency virus positive (HIV+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n* Cluster of differentiation (CD)4 cells >= 500/mm^3\r\n* Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART\r\n* Patients who are HIV+ and do not meet all of these criteria are not eligible for this studyXx_NEWLINE_xXDisease or condition that would preclude safe use of TheraSphere, including concurrent dialysis treatment, or unresolved serious infections including patients who are known HIV positiveXx_NEWLINE_xXPatients with active infections including known human immunodeficiency virus (HIV) are not eligible; HIV positive patients on highly active anti-retroviral therapy (HAART) with undetectable blood HIV levels are eligible; patients with a history or serological evidence of exposure to hepatitis B without active infection are eligible for this studyXx_NEWLINE_xXPatients who are human immunodeficiency virus (HIV)+ (HIV+ patients registered at Fred Hutchinson Cancer Research Center [FHCRC] should be offered treatment on Protocol 1410)Xx_NEWLINE_xXPositive HIV test at screening (except in cohort 3, HPV-associated cancers)Xx_NEWLINE_xXPatients who are known to be human immunodeficiency virus (HIV) positive (+) may be eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n• CD4 cells >= 500/mm^3\r\n• Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART\r\n• No zidovudine or stavudine as part of cART\r\nPatients who are HIV+ and do not meet all of these criteria are not eligible for this studyXx_NEWLINE_xXHIV infectionXx_NEWLINE_xXKnown immunodeficiency or active HIVXx_NEWLINE_xXHuman immunodeficiency virus positive (HIV+) patients will be considered eligible if they are on highly active anti-retroviral therapy (HAART) and have a cluster of differentiation (CD)4 count of >= 200/ul (HIV+ patients who are on HAART and have a CD4 count < 200/ul are eligible if the plasma viral load is below the level of detection according to the local assay)Xx_NEWLINE_xXHIV+ patients who are not on HAART or have a CD4 count of < 200/ul in the presence of detectable plasma viral load according to the local assayXx_NEWLINE_xXKnown infection with HIV, HBV or HCV.Xx_NEWLINE_xXPatients who are HIV positive with a detectable viral load > 750 copies/ml on adequate retroviral therapy must be evaluated for HIV drug resistance test (HIV-1 genotype); these patients may be enrolled only after discussion with the principal investigator (PI) and the infectious disease teamXx_NEWLINE_xXHIV related disease or known or suspected HIV+Xx_NEWLINE_xXPatients who are known to be human immunodeficiency virus (HIV) positive must have a normal cluster of differentiation (CD)4 count and undetectable viral loadXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) are eligible if their CD4 count is >= 350 cells/mm^3 and if they are not taking prohibited cytochrome (CYP)-interacting medicationsXx_NEWLINE_xXClinically significant autoimmune disorders or conditions of immunosuppression; patients with AIDS or HIV-1 associated complex or known to HIV antibody seropositive or known to be recently PCR+ for hepatitis B or C virus are not eligible for this study; virology testing will be done within 6 months of T cell infusion; the severely depressed or altered immune system found in these patients and the possibility of premature death would compromise study objectivesXx_NEWLINE_xXHIV-positive patients on combination antiretroviral therapy which include cytochrome p450 inhibitors are ineligible; patients with CD4 counts less than 300 CD4+ cells/mm^3 and or a high viral load are ineligibleXx_NEWLINE_xXSubjects with HIV infection.Xx_NEWLINE_xXHIV seropositivityXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients are not excluded but, to enroll, must meet all of the below criteria:\r\n* HIV is sensitive to antiretroviral therapy\r\n* Must be willing to take effective antiretroviral therapy, if indicated\r\n* Cluster of differentiation (CD)4 count at screening >= 300 cells/mm^3\r\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions\r\n* If on antiretroviral therapy, must not be taking zidovudine or stavudine\r\n* Must be willing to take prophylaxis for pneumocystis jiroveci pneumonia (PCP) during therapy and until at least 2 months following the completion of therapy or until the CD4 cells recover to over 250 cells/mm^3, whichever occurs laterXx_NEWLINE_xXHIV.Xx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy\r\n* NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) \r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections \r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based testXx_NEWLINE_xXSubjects with documentation of confirmed HIV-1 infection (i.e. HIV-positive), and a hematologic malignancy who meets all other eligibility requirements must:Xx_NEWLINE_xXHIV-positive subjects:Xx_NEWLINE_xXUntreatable HIV infection due to multidrug ARV resistance. Subjects with a detectable or standard viral load > 750 copies/mL should be evaluated with an HIV drug resistance test (HIV-1 genotype). The results should be included as part of the ARV review (described in Appendix D).Xx_NEWLINE_xXKnown HIV infection.Xx_NEWLINE_xXKnown history of HIV infection. Testing for HIV status is not necessary unless clinically indicatedXx_NEWLINE_xXPatients who are HIV positive with an active AIDS-related illness are excluded; patients who are HIV positive but on stable therapy are not excluded.Xx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based testsXx_NEWLINE_xXSeronegative for human immunodeficiency virus (HIV) antibody; the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune function and thus are likely less responsive to the experimental treatmentXx_NEWLINE_xXHas AIDS (HIV positive not excluded)Xx_NEWLINE_xXHas uncontrolled human immunodeficiency virus (HIV) (defined as HIV RNA >500 copies/ml and CD4+ count<200/mm³ on antiretroviral therapy)infection, or hepatitis B (defined as ALT > 1 x ULN, and HBV DNA >2000 IU/ml), or hepatitis C (defined as ALT > 1 x ULN, persistent viremia on antiviral therapy) infections.Xx_NEWLINE_xXHIV or HTLV infectionXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXKnown active HIV, HBV or HCV infectionXx_NEWLINE_xXFor patients with unknown human immunodeficiency virus (HIV) status at the time of enrollment, HIV serology must be tested during screening; patients who are tested positive for HIV could be included if there is an adequate cluster of differentiation 4 (CD4) count (> 350/ul) on a stable regimen of highly active anti-retroviral therapy (HAART) with no detectable or minimal viral burden, and no active infectionsXx_NEWLINE_xXPatient has known human immunodeficiency virus (HIV) or hepatitis B or C infection, as such patients may be at increased risk for toxicity due to concomitant treatment, and disease-related symptoms may preclude accurate assessment of the safety of PBI 05204.Xx_NEWLINE_xXIf HIV+ positive, all patients infected with human immunodeficiency virus (HIV) may be eligible for study provided that their CD4+ count >= 300/uL; their viral load is undetectable; they are currently receiving highly active antiretroviral therapy (HAART)Xx_NEWLINE_xXHIV positive patients receiving antivirals.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; note: HIV testing is not required for entry into this protocolXx_NEWLINE_xXPatient is human immunodeficiency virus (HIV) positive\r\nNote: patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective \r\n* They must have a cluster of differentiation (CD)4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infectionXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients with a known history of HIV infection are not eligible for this trialXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXKnown HIV positive or AIDSXx_NEWLINE_xXKnown human immunodeficiency virus (HIV)-positivity AND actively being treated with highly active anti-retroviral therapy (HAART)Xx_NEWLINE_xXSubjects with uncontrolled human immunodeficiency virus (HIV) are not eligible; controlled HIV is defined as a CD4 count > institutional lower limit of normal and no current co-infection; uncontrolled HIV is all other HIV infection; note that patients with controlled infection should be allowed to participate only if they are not receiving prohibited cytochrome P450 (CYP) interactive medicationsXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXPatients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection who are taking chronic anti-retroviral therapy (HAART) are ineligible if there is a potential for drug-drug interactions with the chemotherapeutic agents; patients with a known confirmed diagnosis of HIV infection who meet standard eligibility criteria and are not taking HAART with a potential for drug-drug interactions are eligibleXx_NEWLINE_xXKnown carrier of HIV.Xx_NEWLINE_xXImmune compromised patients including but not limited to: systemic immune suppressive medications within 6 weeks of enrolling; HIV-positive and below normal CD4 lymphocytes (less than 500 cells per microliter). Patients must be tested for HIV seropositivity and CD4 lymphocyte count to be eligible for the studyXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection may be eligible provided they meet the following criteria:\r\n* CD4-positive cell count >= lower limit of institutional normal\r\n* HIV viral load < 10,000 copies HIV ribonucleic acid (RNA)/mL (if not on anti-HIV therapy) OR < 50 copies HIV RNA/mL (if on anti-HIV therapy)\r\n* No evidence of hepatitis B or C infection\r\n* No evidence of resistant strains of HIV\r\n* No history of acquired immune deficiency syndrome (AIDS)-defining conditionXx_NEWLINE_xXKnown to be HIV positive. HIV testing is not required for those patients who are not known to be positive.Xx_NEWLINE_xXKnown immunodeficiency or active HIV.Xx_NEWLINE_xXKnown HIV carrierXx_NEWLINE_xXHIV-positive.Xx_NEWLINE_xXKnown HIV or AIDs-related illness.Xx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection are eligible provided they meet the following criteria: no evidence of co-infection with hepatitis B or C, cluster of differentiation (CD)4 count >= 400 cells/mm^3, no resistant viral strains, on highly active antiretroviral treatment (HAART) therapy with a viral load < 50 RNA copies/ml, and no history of acquired immunodeficiency syndrome (AIDS)-defining conditionsXx_NEWLINE_xXPatients with a diagnosis of active human immunodeficiency virus (HIV) infection, on anti-retroviral therapy, or with a cluster of differentiation (CD) 4 count less than 200 are ineligible; testing is not required in the absence of clinical findings or suspicionXx_NEWLINE_xXPatients with a diagnosis of active human immunodeficiency virus (HIV) infection, on anti-retroviral therapy, or with a cluster of differentiation (CD)4 count less than 200 are ineligible due to potential interactions between irinotecan and anti-retroviral medications as well as possible immunosuppressive activity of the study treatment; testing is not required in the absence of clinical findings or suspicionXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) are eligible if they are not on antiviral agents and have adequate cluster of differentiation (CD)4 counts (>= 500 mm^3)Xx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients with cluster of differentiation 4 (CD4) counts less than the lower limit of institutional normalXx_NEWLINE_xXPatients known to be human immunodeficiency virus (HIV) positive; HIV testing is not required in the absence of clinical signs and symptoms suggesting HIV infectionXx_NEWLINE_xXHIV-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excludedXx_NEWLINE_xXKnown HIV positive.Xx_NEWLINE_xXKnown infection with HIVXx_NEWLINE_xXKnown diagnosis of human immunodeficiency virus (HIV) infection unless patient is fully immunocompetent (cluster of differentiation 4 [CD4] > 200) and patient is not taking antiretroviral therapyXx_NEWLINE_xXTested positive for HIV or hepatitis.Xx_NEWLINE_xXParticipants known to be human immunodeficiency virus (HIV) positive; testing is not required in the absence of clinical signs and symptoms suggesting HIV infectionXx_NEWLINE_xXKnown HIV positive.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients or cancer survivors are eligible for this study if they fulfill all other eligibility criteriaXx_NEWLINE_xXIndividuals with a known history of human immunodeficiency virus (HIV) positivity may be included in the study as long as they are on appropriate highly active anti-retroviral therapy (HAART) therapyXx_NEWLINE_xXImmunocompromised patients (other than that related to the use of corticosteroids) with the exception of patients known to be human immunodeficiency virus (HIV) positive and have a cluster of differentiation 4 (CD4) count > 400 and do not require antiretroviral therapyXx_NEWLINE_xXHIV infection.Xx_NEWLINE_xXPhase I: patient must not be known to be HIV-positive on combination antiretroviralsXx_NEWLINE_xXExpansion Cohort: patients who have known human immunodeficiency virus (HIV) positivity must be on a 3-drug antiviral regimen that does not include zidovudine and must have a cluster of differentiation (CD4) count > 100/mm^3 and virus load < 5000 copies/mL; they must be placed on a regimen to prevent pneumocystis pneumonia (PCP) reactivation during treatmentXx_NEWLINE_xXKnown HIV infection;Xx_NEWLINE_xXPatients with known HIV, HBV or HCV infection (note: testing for these infections is not required).Xx_NEWLINE_xXSero-positive or nucleic acid test (NAT) positive for human immunodeficiency virus (HIV)Xx_NEWLINE_xXPatients with treated HLTV or HIVXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection are eligible provided their cluster of differentiation 4 (CD4) count is greater than or equal to the institutional lower limit of normal (LLN) (>= 334 cells/uL)Xx_NEWLINE_xXKnown HIV, HBV, HCV infection (except chronic or cleared HBV and HCV infection which will be allowed)Xx_NEWLINE_xXActive infection with HIV, HBV or HCVXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection are eligible; patients with HIV infection must meet the following: no evidence of co-infection with hepatitis B or C; cluster of differentiation (CD)4+ count >= 400/mm; no evidence of resistant strains of HIV; on anti-HIV therapy with an HIV viral load < 50 copies HIV ribonucleic acid (RNA)/mL; no history of acquired immune deficiency syndrome (AIDS) defining conditionsXx_NEWLINE_xXImmunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive, per medical doctor (MD) discretionXx_NEWLINE_xXHistory of HIV infection.Xx_NEWLINE_xXNo human immunodeficiency virus (HIV) infection; patients with a history of intravenous drug abuse or any behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus; patients who test positive or who are known to be infected are not eligible; an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at riskXx_NEWLINE_xXPrior history of HIV-positivity (routine HIV testing is not required pre-treatment)Xx_NEWLINE_xXThe patient is seropositive for HIV 1, HIV 2, HBV, or HCVXx_NEWLINE_xXPatients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.Xx_NEWLINE_xXPositive test for the human immunodeficiency virus (HIV), unless undetectable viral load within 3 months of enrollment (HIV ribonucleic acid [RNA] less than 48 copies/mL) on highly active antiretroviral therapy (HAART) therapyXx_NEWLINE_xXKnown positivity for HIV.Xx_NEWLINE_xXKnown HIV positive statusXx_NEWLINE_xXHIV-1 infection, as documented by a rapid HIV test or any FDA-Approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test kit and confirmed by Western Blot at any time prior to study entry. HIV antigen, plasma HIV-1 RNA, or a secondary antibody test by a method other than rapid HIV and E/CIA is acceptable as an alternative test. Alternatively, if a rapid HIV test or any FDA-Approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test is not available, two HIV-1 RNA values ? 2000 copies/mL at least 24 hours apart performed by any laboratory that has CLIA certification, or its equivalent, may be used to document infection.Xx_NEWLINE_xXUntreatable HIV infection due to multidrug antiretroviral resistance. Patients with a detectable viral load > 750 copies/ml should be evaluated with an HIV drug resistance test (HIV-1 genotype). The results should be included as part of the Antiretroviral Review (described in Appendix D). This Review Committee will make the final determination as to whether HIV viremia could potentially be suppressed with alternate antiretroviral therapy. .Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive patients are not eligible for this protocol; hepatitis B and C positive patients will be evaluated on a case-by-case basisXx_NEWLINE_xXPositive serology for HIVXx_NEWLINE_xXHIV infectionXx_NEWLINE_xXSubject has tested positive for HIV.Xx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) disease will be permitted, only if they are on effective anti-retroviral therapy, have a cluster of differentiation (CD) 4 count greater than 400, and have had no opportunistic infections within the past 6 monthsXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) positive patients; patients do not need to undergo specific screening for HIV to participate in this protocol, but those patients with known or documented infection of HIV are excludedXx_NEWLINE_xXPatients with known human immunodeficiency virus (HIV) must have a CD4 count > 350 and be on concurrent antiretrovirals; patients with a history of intravenous drug abuse or any behavior associated with an increased risk of HIV infection should be tested for exposure to the HIV virus; an HIV test is not required for entry on this protocol, but is required if the patient is perceived to be at riskXx_NEWLINE_xXPatients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART) using combination retroviral agents which are not CYP3A4 inducers or inhibitors\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based testsXx_NEWLINE_xXPatients known to be positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) \r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections \r\n* A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test\r\n* HIV testing is not requiredXx_NEWLINE_xXKnown HIV-positiveXx_NEWLINE_xXKnown human immunodeficiency virus (HIV) infection or a known HIV-related malignancy. Note: HIV testing is not required unless there is any clinical suspicion that the patient might be HIV positive.Xx_NEWLINE_xXHIV positive or an AIDS-related illness;Xx_NEWLINE_xXKnown HIV positiveXx_NEWLINE_xXPatients who are HIV+ will be excludedXx_NEWLINE_xXPatients with known HIV.Xx_NEWLINE_xXHIV infectionXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection must be willing to comply with a regimen of highly active antiretroviral therapy (HAART)Xx_NEWLINE_xXDONOR: HIV-positive donorsXx_NEWLINE_xXKnown history of HIV or underlying immunodeficiencyXx_NEWLINE_xXHuman immunodeficiency virus (HIV) infection; there is theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infectionXx_NEWLINE_xXHIV infection; there is theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infectionXx_NEWLINE_xXDONOR: Infection with HIVXx_NEWLINE_xXHIV or HTLV I/II seropositivityXx_NEWLINE_xXDONOR: History of positive HIV-1 or HIV-2 serology or nucleic acid testXx_NEWLINE_xXKnown HIV infectionXx_NEWLINE_xXKnown HIV positive.Xx_NEWLINE_xXEvidence of HIV infection or HIV positive serology.Xx_NEWLINE_xXKnown HIV or known active HBV or HCV infectionXx_NEWLINE_xXPatients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria: cluster of differentiation 4 (CD4) count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral therapy (HAART) is allowedXx_NEWLINE_xXEvidence of HIV infectionXx_NEWLINE_xXSerologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive Western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and Western blot, or other approved diagnostic testsXx_NEWLINE_xXHIV negative.Xx_NEWLINE_xXSerologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive Western blot, or any other federally approved licensed HIV test; alternatively, this documentation may include a record that another physician has documented that the participant has HIV infection based on prior ELISA and Western blot, or other approved diagnostic testsXx_NEWLINE_xXKnown HIV-positive patients are excluded from the studyXx_NEWLINE_xXKnown positive status for HIVXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of less than 100 mm3 or detectable viral load within past 3 months and receiving anti-retroviral therapy.Xx_NEWLINE_xXTREATMENT: Seronegative for HIV antibodyXx_NEWLINE_xXIf HIV-positive, any cluster of differentiation (CD)4 count will be allowed on studyXx_NEWLINE_xXDocumentation of HIV status; if participant is HIV positive, HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA] test kit, and confirmed by Western blot or other approved test, or HIV rapid multispot antibody differentiation assay); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection\r\n* If the participant is HIV negative, documentation of a negative result for any federally approved, licensed HIV rapid test within 4 weeks prior to study enrollment will suffice; if the initial rapid test is positive, further approved confirmatory test results must be present to document the subject’s HIV statusXx_NEWLINE_xXHas a known history of HIV.Xx_NEWLINE_xXHuman Immunodeficiency Virus (HIV) negative* * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 12 months before screening or at screeningXx_NEWLINE_xXHIV Positive* * Status of HIV must be confirmed via a HIV antibody test or other confirmatory tests available within 12 months before screening or at screeningXx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), cluster of differentiation (CD)4 counts are greater than 350 and viral load is undetectableXx_NEWLINE_xXPatients with HIVXx_NEWLINE_xXBecause of the concerns of potentially harmful interactions of TPI 287and other medications taken by patients who are HIV positive or have AIDS related diseases, patients who are HIV positive are not be eligible for entry into this study. Only patients with suspected HIV will be tested and if positive, will be ineligible.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) positive patients who are not on retroviral therapy will not be excluded from cohort 1, the normal liver function cohort\r\n* HIV positive patients who are not on retroviral therapy will be excluded from cohorts 2-4Xx_NEWLINE_xXKnown HIV infectionXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXKnown HIV infection.Xx_NEWLINE_xXPatient has a known history of HIV infection (testing not mandatory).Xx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients on antiretroviral medications that are CYP3A4 substrates will be closely monitored; HIV-positive patients will be excluded if they have a cluster of differentiation 4 (CD4) count < 200Xx_NEWLINE_xXKnown HIV infectionXx_NEWLINE_xXPositive for HIV infectionXx_NEWLINE_xXPositive HIV test at screeningXx_NEWLINE_xXKnown HIV infection.Xx_NEWLINE_xXHIV-positive patients are ineligibleXx_NEWLINE_xXA history of human immunodeficiency virus (HIV) antibody positive or tests positive for HIV if tested at screeningXx_NEWLINE_xXSubjects with known HIV infectionXx_NEWLINE_xXPatients known to be HIV positiveXx_NEWLINE_xXPatients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective \r\n* They must have a CD4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infectionXx_NEWLINE_xXPositive serological test for HIV, Hep B or Hep C or history of HIV infection, Hepatitis B or Hepatitis C (women with cured HCV will be allowed; subject must have had an serologic test performed within 12 months of informed consent);Xx_NEWLINE_xXHIV infection; patients should provide consent for HIV testing according to the institution’s standard practiceXx_NEWLINE_xXKnown HIV infectionXx_NEWLINE_xXKnown history of HIV infection.Xx_NEWLINE_xXDONOR: History of positive HIV-1 or HIV-2 serology or nucleic acid testXx_NEWLINE_xXKnown HIV infection.Xx_NEWLINE_xXHistory of HIV infection.Xx_NEWLINE_xXIs the subject HIV positive?Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) infection, unless the patient is receiving effective antiretroviral therapy with undetectable viral load and normal CD4 countsXx_NEWLINE_xXKnown HIV infectionXx_NEWLINE_xXImmunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive with low cluster of differentiation (CD)4 count; Note: previous calcineurin inhibitor or previous sirolimus use allowedXx_NEWLINE_xXKown history of HIV.Xx_NEWLINE_xXKnown infection with human immunodeficiency virus (HIV) or subject has tested positive for HIV; patients without prior HIV testing will not be required to be testedXx_NEWLINE_xXPatients who are known to be human immunodeficiency virus (HIV) positive (+) are eligible providing they meet all of the following additional criteria within 28 days prior to registration:\r\n* Cluster of differentiation (CD) 4 cells >= 500/mm^3\r\n* Viral load < 50 copies of HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies of HIV mRNA if not on cART\r\n* No zidovudine or stavudine as part of cART; patients who are HIV+ and do not meet all of these criteria are not eligible for this studyXx_NEWLINE_xXKnown HIV positivity or AIDS-related illnessXx_NEWLINE_xXHIV-positive patientsXx_NEWLINE_xXKnown HIV or AIDs.Xx_NEWLINE_xXKnown HIV positivity (testing not required).Xx_NEWLINE_xXImmunocompromised patients or patients known to be human immunodeficiency virus (HIV) positive and currently receiving combination antiretroviral therapy; patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXHIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 ribonucleic acid (RNA) viral load; NOTE: The term “licensed” refers to a U.S Food and Drug Administration (FDA)-approved kit or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally; WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a western blot or a plasma HIV-1 RNA viral loadXx_NEWLINE_xXAcute active (such as tuberculosis or malaria), serious, uncontrolled infection; participants with a CD4 count =< 50/mm^3 (0.05 x 10^9/L) will be excluded if they have had an opportunistic infection within the past 3 months, or if there is evidence of resistance to antiretroviral therapy (i.e., HIV viral load >= 400 copies/mL despite combination antiretroviral therapy for at least 4 months)Xx_NEWLINE_xXKnown HIV positive or Hepatitis A, B, or C infectionXx_NEWLINE_xXHIV infectionXx_NEWLINE_xXThe patient is known to be positive for Human Immunodeficiency Virus (HIV) or has another confirmed or suspected immunosuppressive or immunodeficient condition (patients with thyroiditis are eligible)Xx_NEWLINE_xXKnown to be HIV positive or to have an AIDS-related illness.Xx_NEWLINE_xXPositive for human immunodefinciency (HIV) infectionXx_NEWLINE_xXBecause of compromised cellular immunity and limited capacity to respond to vaccination, patients who are human immunodeficiency virus (HIV)+ will be excludedXx_NEWLINE_xXIf human immunodeficiency virus (HIV) positive, cluster of differentiation 4 (CD4) count must be >= 400Xx_NEWLINE_xXImmunocompromised patients (other than that related to the use of corticosteroids) including patients known to be HIV positive with a CD4 count of < 400Xx_NEWLINE_xXPositive test for HIV antibodiesXx_NEWLINE_xXChronic or currently active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment including, but not limited to: chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, active Hepatitis C, and known HIV disease. All Human Immunodeficient virus (HIV)-positive subjects are excluded from this study, regardless of whether they have an Acquired Immunodeficiency Syndrome (AIDS) defining disease and/or are on antiviral therapy.Xx_NEWLINE_xXKnown positive test for HIVXx_NEWLINE_xXSerologic documentation of HIV infection at any time prior to study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), positive Western Blot, or any other federally approved licensed HIV test; a positive HIV viral load prior to study entry will also be permittedXx_NEWLINE_xXKnown human immunodeficiency virus (HIV)-seropositive and are taking anti-retrovirals may not participate in this study; participants who are HIV-seropositive and not on anti-retroviral therapy and who otherwise meet the inclusion/exclusion criteria will be eligible for the studyXx_NEWLINE_xXHas known HIV or AIDS infectionXx_NEWLINE_xXKnown HIV or AIDSXx_NEWLINE_xXKnown HIV or AIDSXx_NEWLINE_xXKnown HIV or AIDSXx_NEWLINE_xXHIV positiveXx_NEWLINE_xXPatients with acquired immune deficiency syndrome (AIDS) based upon current Center for Disease Control (CDC) definition or patients known to be human immunodeficiency virus (HIV) positive; note, however, that HIV testing is not required for entry into this protocol; the need to exclude these patients from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressiveXx_NEWLINE_xXThe patient is known to be HIV-positive.Xx_NEWLINE_xXHIV infection with a last known or suspected CD4 count of <50/mm3Xx_NEWLINE_xXHistory of HIV disease and/or treatment with anti-HIV agents.Xx_NEWLINE_xXHIV positiveXx_NEWLINE_xXKnown HIV infectionXx_NEWLINE_xXThe patient is known to be HIV-positive.Xx_NEWLINE_xXKnown HIV+ patients.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV) infection, unless receiving effective antiretroviral therapy with undetectable viral load and normal CD4 countsXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXSeronegative for human immunodeficiency virus (HIV) antibody; Note: The experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatmentXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXSerologic evidence of HIVXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy (HIV testing not required); NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state (cluster of differentiation [CD]4 > 200, viral load undetectable, on antiretroviral therapy), are eligible for this trialXx_NEWLINE_xXStandard blood tests that are positive for HIV infectionXx_NEWLINE_xXA positive HIV test result (enzyme-linked immunosorbent assay [ELISA] and Western blot) or history of known HIV; an HIV test will not be required; however, previous medical history will be reviewedXx_NEWLINE_xXPatients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective \r\n* They must have a CD4 count of greater than 250 cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection\r\n* Must be on antiretroviral therapy and there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment\r\n* HIV viral load must be < 200 copies/ mm^3 by standard clinical assaysXx_NEWLINE_xXSubject has active infection with HIV, HBV, HCV or HTLV as defined below:Xx_NEWLINE_xXPositive serology for HIVXx_NEWLINE_xXKnown HIV positive.Xx_NEWLINE_xXKnown HIV positive patients.Xx_NEWLINE_xXSubject is HIV positiveXx_NEWLINE_xXHIV-1 infection, as documented by a rapid HIV-1 test or any Food and Drug Administration (FDA)-approved HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit and confirmed by western blot at any time prior to study entry; alternatively, two HIV-1 RNA values > 200 copies/mL at least 24 hours apart performed by any laboratory that has Clinical Laboratory Improvement Amendments (CLIA) certification, or its equivalent may be used to document infectionXx_NEWLINE_xXDONOR: HIV positiveXx_NEWLINE_xXHIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (documentation may be a record of an ART prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name; receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis [PrEP] regimen alone [e.g., Truvada], which is exclusionary);\r\n* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n** NOTE: A “licensed” assay refers to a United States (U.S.) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studiesXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trialXx_NEWLINE_xXSubjects known to be seropositive for HIV or for HTLV-IXx_NEWLINE_xXMales who self-identify as having had or currently having sex with men; both human immunodeficiency virus (HIV)-infected and HIV-uninfected subjects are being enrolledXx_NEWLINE_xXImmunocompromised (positive human immunodeficiency virus [HIV] test, transplant recipient, received chemotherapy for cancer, or taking immunosuppressant drugs)Xx_NEWLINE_xXHIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n* Documentation of HIV diagnosis in the medical record by a licensed health care provider;\r\n* Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (documentation may be a record of an ART prescription in the participant’s medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant’s name; receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis [PrEP] regimen alone [e.g., Truvada], which is exclusionary);\r\n* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 1000 RNA copies/mL;\r\n* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 western blot confirmation or HIV rapid multispot antibody differentiation assay\r\n* NOTE: A “licensed” assay refers to a United States (US) Food and Drug Administration (FDA)-approved assay, which is required for all investigational new drug (IND) studiesXx_NEWLINE_xXPatients seropositive for HIV-1 or -2Xx_NEWLINE_xXImmune deficiency disease or known history of HIV, HBV, HCVXx_NEWLINE_xXKnown active infection with HIVXx_NEWLINE_xXKnown HIV infection.Xx_NEWLINE_xXKnown active infection with HIVXx_NEWLINE_xXHIV-1 infection, documented by one of the following any time prior to study entry:\r\n* Any licensed rapid HIV test\r\n* HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit; and confirmed by one of the following:\r\n* Licensed western blot\r\n* Second antibody test by a method other than the initial rapid HIV and/or E/CIA\r\n* HIV-1 antigen\r\n* Plasma HIV-1 RNA viral load\r\n* Documentation of receipt of antiretroviral therapy\r\n* Note: the term “licensed” refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally; WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment; a reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a western blot or a plasma HIV-1 RNA viral loadXx_NEWLINE_xXDocumented human immunodeficiency virus (HIV) infection, genital warts, chancroid, or pelvic inflammatory disease that will require long term treatmentXx_NEWLINE_xXPositive HIV testXx_NEWLINE_xXPositive viral test for HIV-1, HIV-2, HBV, HCV, Treponema pallidum, HTLV 1 (if tested), HTLV-2 (if tested), or WNV (if tested)Xx_NEWLINE_xXPatients who have HIV, Hepatitis A, B or C or CMV reactivationXx_NEWLINE_xXEvidence of HIV infection or known HIV positive serology.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV)-positive patients who are not receiving: agents with the potential for PK interactions with romidepsin or hepatotoxic antiretrovirals (nucleoside reverse-transcriptase inhibitors [NRTIs]: abacavir, didanosine, emtricitabine, lamivudine, stavudine, and zidovudine), dual protease inhibitor (PI)-based regimens except low-dose boosting with ritonavir, atazanavir, indinavir, maraviroc, and nevirapine may be eligible; additionally, the HIV-positive patients should have a cluster of differentiation (CD)4 count > 250/mm^3; if the specific cause of hepatic dysfunction is unknown, the patient should be worked up for other viral causes of hepatitis and their eligibility determined after consultation with the principal investigatorXx_NEWLINE_xXDonors who are HIV positive (Patients who are HIV positive - if autologous product)Xx_NEWLINE_xXHIV-positive patient at Thomas Street Health CenterXx_NEWLINE_xXKnown history of HIV seropositivity;Xx_NEWLINE_xXHIV-1 infection as documented by any federally approved, licensed HIV test performed in conjunction with screening (enzyme linked immunosorbent assay [ELISA], Western blot or other approved test); alternatively, this documentation may include a record that another physician has documented that the patient has HIV based on prior ELISA and western blot, or other approved diagnostic tests; if the participant’s HIV status is documented by an outside physician, the protocol team strongly recommends obtaining a copy of the HIV laboratory reports from this physician; all confirmatory tests and the physician’s note must be on file before the participant is enrolled; in the rare circumstance where only an outside physician’s note with no supporting laboratory documentation is available, the local site should have additional tests performed to verify the participant’s HIV status; one of the following additional tests should be performed:\r\n* A rapid HIV test\r\n* ELISA and Western blot\r\n* Chemiluminescence immunoassay and Western blot\r\n* HIV ribonucleic acid (RNA) > 2000 copies/mL\r\n* HIV antigen testXx_NEWLINE_xXImmunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive (HIV 1/2 antibodies) and currently receiving antiretroviral therapyXx_NEWLINE_xXPatients who are known to be human immunodeficiency virus (HIV)-positive will be excluded as highly active antiretroviral therapy (HAART) and HIV itself are known to cause peripheral neuropathyXx_NEWLINE_xXHIV positiveXx_NEWLINE_xXAny HIV statusXx_NEWLINE_xXKnown HIV or AIDS-related illnessXx_NEWLINE_xXThe patient is known to be positive for the human immunodeficiency virus (HIV). The effect of BPM31510 on HIV medications is unknown. Note: HIV testing is not required for eligibility, but if performed previously and was positive, the patient is ineligible for the study.Xx_NEWLINE_xXHuman immunodeficiency virus (HIV)+ positive patients are eligible if their CD4+ count >= 300/uL and they have an undetectable viral load; in addition, they must be currently receiving highly active antiretroviral therapy (HAART) and be under the care of an infectious diseases specialistXx_NEWLINE_xXPositive serology for HIV.Xx_NEWLINE_xX